Tau-PET signal in Alzheimer's disease is related to immune activation and synaptic signaling measured with CSF proteomics

被引：0
|
作者：
Van de Giessen, E. [1 ]
Rikken, R. M. [1 ]
Vromen, E. [1 ]
Coomans, E. M. [1 ]
Visser, D. [1 ]
Barkhof, F. [1 ]
Collij, L. E. [1 ]
Boellaard, R. [1 ]
Golla, S. V. S. [1 ]
van Berckel, B. N. M. [1 ]
Ossenkoppele, R. [1 ]
den Braber, A. [1 ]
Vijverberg, J. [1 ]
van der Flier, W. M. [1 ]
Pijnenburg, Y. A. L. [1 ]
Teunissen, C. E. [1 ]
Visser, P. J. [1 ]
Tijms, B. [1 ]
机构：
[1] Amsterdam UMC, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-109
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [41] Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related α-synucleinopathies
    Muntane, G.
    Dalfo, E.
    Martinez, A.
    Ferrer, I.
    NEUROSCIENCE, 2008, 152 (04) : 913 - 923
  • [42] Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study
    Lagarde, Julien
    Olivieri, Pauline
    Tonietto, Matteo
    Rodrigo, Sebastian
    Gervais, Philippe
    Caille, Fabien
    Moussion, Martin
    Bottlaender, Michel
    Sarazin, Marie
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [43] Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer′s Disease Study (LEADS)
    Cho, Hanna
    Mundada, Nidhi S.
    Apostolova, Liana G.
    Carrillo, Maria C.
    Shankar, Ranjani
    Amuiri, Alinda N.
    Zeltzer, Ehud
    Windon, Charles C.
    Soleimani-Meigooni, David N.
    Tanner, Jeremy A.
    Heath, Courtney Lawhn
    Lesman-Segev, Orit H.
    Aisen, Paul
    Eloyan, Ani
    Lee, Hye Sun
    Hammers, Dustin B.
    Kirby, Kala
    Dage, Jeffrey L.
    Fagan, Anne
    Foroud, Tatiana
    Grinberg, Lea T.
    Jack, Clifford R.
    Kramer, Joel
    Kukull, Walter A.
    Murray, Melissa E.
    Nudelman, Kelly
    Toga, Arthur
    Vemuri, Prashanthi
    Atri, Alireza
    Day, Gregory S.
    Duara, Ranjan
    Graff-Radford, Neill R.
    Honig, Lawrence S.
    Jones, David T.
    Masdeu, Joseph
    Mendez, Mario
    Musiek, Erik
    Onyike, Chiadi U.
    Riddle, Meghan
    Rogalski, Emily J.
    Salloway, Stephen
    Sha, Sharon
    Turner, Raymond Scott
    Wingo, Thomas S.
    Wolk, David A.
    Koeppe, Robert
    Iaccarino, Leonardo
    Dickerson, Bradford C.
    La Joie, Renaud
    Rabinovici, Gil D.
    ALZHEIMERS & DEMENTIA, 2023, 19 : S98 - S114
  • [44] Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies
    Dilcher, Roxane
    Wall, Stephan
    Gross, Mattes
    Katzdobler, Sabrina
    Wagemann, Olivia
    Palleis, Carla
    Weidinger, Endy
    Fietzek, Urban
    Bernhardt, Alexander
    Kurz, Carolin
    Ferschmann, Christian
    Scheifele, Maximilian
    Zaganjori, Mirlind
    Gnoerich, Johannes
    Buerger, Katharina
    Janowitz, Daniel
    Rauchmann, Boris-Stephan
    Stoecklein, Sophia
    Bartenstein, Peter
    Villemagne, Victor
    Seibyl, John
    Sabri, Osama
    Barthel, Henryk
    Perneczky, Robert
    Schoeberl, Florian
    Zwergal, Andreas
    Hoeglinger, Guenter U.
    Levin, Johannes
    Franzmeier, Nicolai
    Brendel, Matthias
    ALZHEIMERS & DEMENTIA, 2024, 20 (10) : 6896 - 6909
  • [45] Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET
    Oliver Goldhardt
    Inanna Warnhoff
    Igor Yakushev
    Ilijana Begcevic
    Hans Förstl
    Viktor Magdolen
    Antoninus Soosaipillai
    Eleftherios Diamandis
    Panagiotis Alexopoulos
    Timo Grimmer
    Translational Neurodegeneration, 8
  • [46] Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET
    Goldhardt, Oliver
    Warnhoff, Inanna
    Yakushev, Igor
    Begcevic, Ilijana
    Foerstl, Hans
    Magdolen, Viktor
    Soosaipillai, Antoninus
    Diamandis, Eleftherios
    Alexopoulos, Panagiotis
    Grimmer, Timo
    TRANSLATIONAL NEURODEGENERATION, 2019, 8 (01)
  • [47] Biomarkers of Alzheimer's disease: Correlations between CSF p-TAU levels and cerebral glucose metabolism assessed with PET
    Borghetti, D.
    Giorgetti, A.
    Rossi, C.
    Kiferle, L.
    Frosini, D.
    Sassi, N.
    Petrozzi, L.
    Neglia, D.
    Murri, L.
    Ceravolo, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 196 - 196
  • [48] Changes in synaptic density in relation to tau deposition in prodromal Alzheimer's disease: a dual protocol PET-MR study
    Vanhaute, H. R. J.
    Ceccarini, J.
    Michiels, L.
    Sunaert, S.
    Lemmens, R.
    Emsell, L.
    Vandenbulcke, M.
    Van Laere, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S177 - S178
  • [49] Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers
    Binnewijzend, Maja A. A.
    Adriaanse, Sofie M.
    Van der Flier, Wiesje M.
    Teunissen, Charlotte E.
    de Munck, Jan C.
    Stam, Cornelis J.
    Scheltens, Philip
    van Berckel, Bart N. M.
    Barkhof, Frederik
    Wink, Alle Meije
    HUMAN BRAIN MAPPING, 2014, 35 (05) : 2383 - 2393
  • [50] Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer's disease continuum: biological and methodological perspectives from disease heterogeneity (vol 15, 37, 2023)
    Mohanty, Rosaleena
    Ferreira, Daniel
    Nordberg, Agneta
    Westman, Eric
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
12345